BIOATLA REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 data in squamous cell carcinoma of the head and neck (SCCHN) showed multiple confirmed responses and manageable safety profile; anticipate FDA meeting for SCCHN potential registrational trial in 2H 2024 – Evalstotug (CTLA-4 antibody) Phase 1 study progressing well, anticipate clearing dose- limiting toxicity (DLT) observation period with 1 gram (14.2 mg/kg) in 2Q 2024 and initial ...